Torsdag 31 Oktober | 23:52:49 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-26 - Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-08-14 - Kvartalsrapport 2024-Q2
2024-05-30 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2024-05-29 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-04-05 - Extra Bolagsstämma 2024
2024-02-28 - Bokslutskommuniké 2023
2023-12-20 - Extra Bolagsstämma 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-07-24 - Kvartalsrapport 2023-Q2
2023-05-29 - Årsstämma
2023-05-16 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2023-05-08 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-16 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2022-05-13 - Kvartalsrapport 2022-Q1
2022-05-13 - Årsstämma
2022-04-08 - Extra Bolagsstämma 2022
2022-02-16 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2021-05-07 - Årsstämma
2021-05-07 - Kvartalsrapport 2021-Q1
2021-02-16 - Bokslutskommuniké 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-06-05 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2020-06-04 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-12-19 - Extra Bolagsstämma 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-08-13 - Kvartalsrapport 2019-Q2
2019-05-09 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2019-05-08 - Årsstämma
2019-05-08 - Kvartalsrapport 2019-Q1
2019-02-12 - Bokslutskommuniké 2018
2018-11-20 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-07-25 - Extra Bolagsstämma 2018
2018-05-09 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2018-05-08 - Kvartalsrapport 2018-Q1
2018-05-08 - Årsstämma
2018-02-20 - Bokslutskommuniké 2017
2017-11-21 - Kvartalsrapport 2017-Q3
2017-08-22 - Kvartalsrapport 2017-Q2
2017-05-11 - Kvartalsrapport 2017-Q1
2017-05-11 - Årsstämma
2017-04-22 - Bokslutskommuniké 2016
2016-11-11 - Kvartalsrapport 2016-Q3
2016-09-21 - Extra Bolagsstämma 2016
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-18 - Kvartalsrapport 2016-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHandel & varor
IndustriDagligvaror
Simris Group är ett bioteknikbolag. Bolaget är inriktat mot forskning och utveckling samt tillverkning av bioaktiva ämnen från odlade mikroalger, för tillämpningar inom nutrition, cosmeceuticals och läkemedel. Bolagets teknik ersätter även ohållbara råvaror från hotade arter och känsliga marina ekosystem. Första produkten är omega-3-tillskott som säljs under eget varumärke. Simris Group grundades 2011 och har sitt huvudkontor i Hammenhög.
2024-03-12 21:10:00

Simris Group AB has today, March 12th, 2023, announced the appointment of Dr. Alexis Roberts-McIntosh, a highly experienced pharmaceutical industry executive, to the position of Group CEO. Alexis Roberts-McIntosh replaces current CEO Julian Read, who will be retained as an Advisor for a handover period of 3 months. Julian Read steps back from the Company in order to pursue other opportunities and will ensure a seamless transfer of knowledge to Alexis Roberts-McIntosh during the handover period.

The Board of Simris Group has previously communicated its strategy to focus resources on its wholly-owned subsidiary, Simris Biologics GmbH, which develops cytotoxic compounds from cyanobacteria for inclusion in Antibody Drug Conjugates (ADC) and which is now likely to be less than 12 months away from securing its first license agreement. In anticipation of this, the Board has therefore committed to strengthening leadership through the appointment of a CEO with an appropriate background and track record in the Pharma sector, to ensure the successful commercialisation of its ADC-platform and eventual expansion into other areas.

Dr. Roberts-McIntosh's appointment is an integral part of the strategic turnaround of the Simris Group's activities, which is underpinned by the shift in focus of the company from the low-margin and highly competitive dietary supplement space to the high-margin ADC payload pharmaceutical space - where the company's product has a sustainable competitive advantage underpinned by its broad patent protection.

In the last 22 months considerable work has been done by outgoing CEO, Julian Read, to redefine Simris' corporate objectives, complete the acquisition of Cyano Biotech GmbH (since renamed Simris Biologics), and bring the Group substantially closer to securing its first ADC license agreement with a drug developer. These actions, combined with the funding support received from Simris Chairman Steven Schapera and other strategic shareholders, ensures that Dr. Roberts-McIntosh inherits a company that has a clear strategy, is operating efficiently, and is funded appropriately.

Dr. Roberts-McIntosh holds a Ph.D in Medicinal Chemistry. She began her career with GlaxoSmithKline and has since spent the last 27 years transitioning upward through ever-more senior appointments at some of world's most iconic pharmaceutical companies including Pfizer, Johnson & Johnson, Reckitt Benckiser, and Abbott. She is highly entrepreneurial, has an unblemished record of driving innovative products to commercialisation, and has managed complex teams and large P&L’s. By any measure, Alexis is an accomplished leader with a proven history of delivering outstanding sales growth with accompanying profitability.

The Board thanks Julian for his hard work in transforming Simris from being an Omega-3 pure-player into a competitive biotech company preparing to serve the world’s largest pharmaceutical companies with novel active compounds to use in their drug development pipeline. The Simris business is in a stronger position now than it has ever been, and remains committed to its path of transformation and the commercialisation of its ADC-platform.

On the appointment of Dr. Roberts-McIntosh, Mr. Schapera commented: "I have known Alexis since about 2018 and always knew the time would come when we would work together. Alexis has years of experience bringing pharma and consumer products to market, and her global experience in Big Pharma is just what we need right now, to strengthen our position in the ADC space with drug developers and secure our first license agreement. Our outgoing CEO Julian Read has done a phenomenal job in getting us to where we are today, and he now hands over the baton to Alexis. Julian, in combination with our CFO Christoffer Tell, and our scientific team in Berlin headed by Dr. Dan Enke and Dr. Heike Enke will work collaboratively with Alexis in coming months to ensure the transfer of knowledge is as seamless as possible.”
Dr. Roberts-McIntosh added “Simris Biologics holds an extremely strong position in the ADC payload space. It's also sitting on the world's largest strain library of cyanobacteria. I am excited at the prospect of unlocking and adding value, both at the Simris Biologics level as well as to the broader Group. The opportunity to build a substantial business around products and services that do good for people and the planet is a rare one and I am excited to be joining the Team.”
Julian Read commented, “I have thoroughly enjoyed working with the staff and the Board and wish them every success for the future. I have taken this difficult decision for entirely personal reasons, and this should not be interpreted as any lack of belief on my part for the ambitions of the Simris Group. I firmly believe that the ADC-technology platform will enable the successful treatment of cancer patients and will develop significant value for shareholders. Simris now has the opportunity to bring in a leader with far more experience in pharmaceuticals, and to deliver on this potential.